MAPT and Alzheimer disease: Further, higher levels of phosphorylated tau (P-tau) in the OBs of AD patients correlate with MC loss, impaired dendro-dendritic inhibition, and diminished olfactory detection abilities before cognitive impairments emerged (Li et al., 2019a).